Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients: the need for randomized trials.
Vitamin D has been used in the context of secondary hyperparathyroidism in patients with end-stage renal disease. A wave of recent studies suggests that vitamin D treatment may be associated with decreased mortality risk in these patients. The article by Wolf et al. further supports these studies by identifying vitamin D deficiency as a risk factor for early mortality in incident hemodialysis patients.
Al-Aly
Z
Z
Division of Nephrology, Saint Louis University, Saint Louis, Missouri 63110, USA. zalaly@slu.edu
D006801:Humans; D006961:Hyperparathyroidism / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000378:metabolism* / Q000628:therapy; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis / Q000009:adverse effects*; D012307:Risk Factors; D016019:Survival Analysis; D014807:Vitamin D / Q000378:metabolism* / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism
D014807:Vitamin D